Vaccine, update at 7 pm Italy: 21,358,067 doses
Gelmini: "In two weeks we complete vaccination of fragile people"
Vaccines, in Lazio reduced incidence of hospitalizations by 91% for over 80s
Share
May 05, 2021 Subjects who received the first dose of the AstraZeneca vaccine without developing rare thrombosis events "have no contraindication for a second administration of the same type of vaccine". Thus the opinion of the Cts transmitted with a new circular from the Ministry of Health. Rare thrombosis appears to have occurred only after the first dose. This position, affirms the CTS, "could possibly be revised if different evidences emerge in the coming weeks deriving in particular from the analysis of the safety profile of the vaccine in subjects who received the 2 / a dose in the UK".
The circular, signed by the Director of Prevention of the Ministry of Health Gianni Rezza, transmits the opinion of the CTS relating to 30 April. In the opinion, the CTS explains that "on the basis of the information available to date on the onset of thrombosis in unusual locations (thrombosis of the cerebral venous sinuses, splanchnic thrombosis, arterial thrombosis) associated with thrombosis, reported to have occurred only after the first dose of the vaccine of AstraZeneca, subjects who received the first dose of this vaccine without developing this type of event, do not have contraindications for a second administration of the same type of vaccine ".
Extend Pfizer-Moderna recall to 42 days
An extension in the administration of the second dose of Pfizer-BioNtech and Moderna mRNA vaccines "in the sixth week after the first dose" is "recommended". This is foreseen by the circular of the Ministry of Health which transmits the opinion of the CTS regarding the extension of the interval between the two doses of mRNA vaccines. The CTS notes that "there remains a significant number of unvaccinated subjects who, due to their personal characteristics or concomitant pathologies, are at high risk of developing serious or fatal forms of COVID-19". Based on this, the CTS recommends a prolongation in the administration of the second dose.
With the circular - signed by the Director of Prevention of the Ministry of Health Gianni Rezza - the opinion of the Technical Scientific Committee CTS relating to April 30 is transmitted regarding the extension of the interval between the two doses of mRNA vaccines and the second dose of the vaccine Vaxzevria. This consideration on the extension of the times for the booster with the two vaccines Pfizer and Moderna, notes the Cts, finds its rationale in the following observations: "the administration of the second dose within 42 days from the first does not affect the effectiveness of the immune response "and" the first administration of both RNA vaccines already confers effective protection against the development of severe COVID-19 disease in a high percentage of cases (greater than 80%) ".
Furthermore, "in a scenario in which there is still a need in the country to cover a high number of subjects at risk of developing serious or even fatal forms of COVID-19 - states the Scientific Technical Committee - conditions arise in which priority should be given to public health strategies that make it possible to cover as many subjects as possible from risk in the shortest possible time ". The opinion, reads the circular, "may in the future be supported by further epidemiological analysis on: lethality by age group, infected by age group (current data of new infections), estimate of the infected also modeled with respect to the data of the prevalence study ".